Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsEntirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesCrystal structure of the enzyme CapF of Staphylococcus aureus reveals a unique architecture composed of two functional domainsCloning of genes affecting capsule expression in Staphylococcus aureus strain M.Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureusSensitivity and specificity of an improved rapid latex agglutination test for identification of methicillin-sensitive and -resistant Staphylococcus aureus isolates.Staphylococcus aureus capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils in vitroStaphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model.Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence.Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides.Genetic and serologic evaluation of capsule production by bovine mammary isolates of Staphylococcus aureus and other Staphylococcus spp. from Europe and the United States.Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus.Functional analysis of the Staphylococcus aureus collagen adhesin B domainClonal associations among Staphylococcus aureus isolates from various sites of infectionStaphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression.The capsular polysaccharide of Staphylococcus aureus is attached to peptidoglycan by the LytR-CpsA-Psr (LCP) family of enzymesLaboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein AAntibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolatesVaccine assembly from surface proteins of Staphylococcus aureus.Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strainsHeterogeneity of cell-associated CP5 expression on Staphylococcus aureus strains demonstrated by flow cytometry.A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.Comparison of Capsular Typing of Staphylococcus aureus with Bacteriophage Typing: A Study in Gulbarga, India.Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus.An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children.Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureusStaphylococcus aureus capsular polysaccharides.USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests.Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureusPhase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremiaCharacterization of a new variant of IS257 that has displaced the capsule genes within bovine isolates of Staphylococcus aureus.Analysis of methicillin-resistant and methicillin-susceptible Staphylococcus aureus by a molecular typing method based on coagulase gene polymorphisms.Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionateMsaB activates capsule production at the transcription level in Staphylococcus aureus.Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytesReactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide.
P2860
Q24646677-E19FF71E-7C20-4D2A-9356-A6A7923581F5Q26746887-2A3BE707-A01D-4BA8-876E-5F5641C66F40Q27677173-E9AEF7BD-193D-4BD8-AA07-4A532BD21497Q33226172-2837EE7D-BFB6-4715-AA84-DBBC6678DF10Q33595610-55BB476B-9BE1-486F-8102-2DBD5E2B1D02Q33662059-4107AED2-C67C-402D-8D6F-07B042241657Q33716167-82BBA785-63AA-422D-8F83-DE356B9854DCQ33767412-F49A9325-E96E-4A12-934A-608189741720Q33788238-BD438FAA-FBBE-49CF-BB74-6FB324744D8BQ33931083-2B75AC59-5957-46D7-84A2-F9C00CBE7F87Q33968870-294AF0D8-54C2-4833-B43F-0517D683B59DQ33991770-DE703423-7601-4628-B994-7230CAFB5EDCQ34001400-3EA93929-F023-4CD9-BC07-263EAF3C9864Q34005637-48D28E87-E6A5-4A89-8C60-CC6F31BA70EAQ34005978-9F598CE4-EC44-4309-9E56-8D82BE3321E0Q34076020-167459AF-9578-4E81-8994-05BF7F17C8E8Q34526987-2F855D9F-B019-445B-9F36-B6FC50DD4316Q34595644-2142CA7D-1EB9-43DA-8406-9EB74D9EDAF8Q35130822-78E8C8EC-00EA-47F4-96E3-6D3CC41655CAQ35224198-AFC29AE3-4826-4D13-9DA6-E24675092A29Q35229468-6629A4F1-B874-4411-8D0F-31E35238EE22Q35489404-CE0233EF-828F-49AD-8AE1-AA5BAF14639BQ35533053-EEEA064E-0719-4870-9A8F-5CBF121FD87EQ35605034-53D2014A-ED8A-4CC5-9679-7D4FF242833AQ35618211-593CA0F0-F9DC-4794-86DD-52EA9A5FFBABQ35620548-82456B24-A5DA-4403-ADF9-5A3EE58EB9EFQ35630504-C3538C44-3330-4E29-9DDC-C4F54991379EQ35677495-9532CCDB-C279-42C3-94AD-52A980BE4693Q35690743-A48824A9-1387-4D24-BAD7-477A8FA34EA6Q35980398-814247BD-3B42-4A20-9115-150343C25903Q36313264-AFF4A097-7570-4456-9DB3-C75DE92B3EA6Q36313848-C5BCD794-0E9E-4F62-B045-9577EB231B73Q36504403-E3D1F260-F63F-4269-BDB5-B1025A28ABFFQ36942862-FAD5E8D3-3794-492E-AC34-31F5D6CAD5D7Q36958120-9B2CDCBF-9E05-420E-9294-F7E8EAC5EDC6Q36966028-5B4857EB-4ED5-4B6D-AB09-E6ABE960185FQ36974536-120EA936-2D87-4111-A33C-A4537C373B16Q36985988-6B61DCF3-882B-41CF-A865-0FCB2A0D0A7DQ37003768-4458AAC8-D51E-4741-B4E0-C3736C565D2CQ37050644-532FF539-5A73-4B30-83BA-2D5BAE7DB3EC
P2860
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@en
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@nl
type
label
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@en
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@nl
prefLabel
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@en
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@nl
P2093
P1476
Predominance of two newly desc ...... ates of Staphylococcus aureus.
@en
P2093
P356
10.1016/0732-8893(84)90002-6
P577
1984-04-01T00:00:00Z